Sökning: WFRF:(Hertzberg Mark) >
Reduced-Intensity A...
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
-
- Klyuchnikov, Evgeny (författare)
- Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.
-
- Bacher, Ulrike (författare)
- Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany.
-
- Kroeger, Nicolaus M. (författare)
- Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.
-
visa fler...
-
- Hari, Parameswaran N. (författare)
- Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
-
- Ahn, Kwang Woo (författare)
- Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
-
- Carreras, Jeanette (författare)
- Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
-
- Bachanova, Veronika (författare)
- Univ Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA.
-
- Bashey, Asad (författare)
- Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.
-
- Cohen, Jonathon B. (författare)
- Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA.
-
- D'Souza, Anita (författare)
- Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
-
- Freytes, Cesar O. (författare)
- South Texas Vet Hlth Care Syst, San Antonio, TX USA.;Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.;Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.
-
Gale, Robert Peter (författare)
-
- Ganguly, Siddhartha (författare)
- Univ Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA.
-
- Hertzberg, Mark S. (författare)
- Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia.
-
- Holmberg, Leona A. (författare)
- Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
-
- Kharfan-Dabaja, Mohamed A. (författare)
- H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
-
- Klein, Andreas (författare)
- Tufts Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA USA.
-
- Ku, Grace H. (författare)
- Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, San Diego, CA 92103 USA.
-
- Laport, Ginna G. (författare)
- Stanford Hosp & Clin, Div Bone Marrow Transplantat, Stanford, CA USA.
-
- Lazarus, Hillard M. (författare)
- Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA.
-
- Miller, Alan M. (författare)
- Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA.
-
- Mussetti, Alberto (författare)
- Fdn IRCCS Ist Nazl Tumori, SC Ematol & Trapianto Midollo Osseo, Milan, Italy.;Univ Milan, Milan, Italy.
-
- Olsson, Richard F. (författare)
- Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.
-
- Slavin, Shimon (författare)
- Int Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel.
-
- Usmani, Saad Z. (författare)
- Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol, Med Oncol, Charlotte, NC USA.
-
- Vij, Ravi (författare)
- Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA.
-
- Wood, William A. (författare)
- Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA.
-
- Maloney, David G. (författare)
- Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
-
- Sureda, Anna M. (författare)
- Hosp Duran & Reynals, Inst Catala Oncol, Serv Hematol, Barcelona, Spain.;European Grp Blood & Marrow Transplantat, Milan, Italy.
-
- Smith, Sonali M. (författare)
- Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA.
-
- Hamadani, Mehdi (författare)
- Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
-
visa färre...
-
Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany. (creator_code:org_t)
- Elsevier BV, 2015
- 2015
- Engelska.
-
Ingår i: Biology of blood and marrow transplantation. - : Elsevier BV. - 1083-8791 .- 1523-6536. ; 21:12, s. 2091-2099
- Relaterad länk:
-
http://www.bbmt.org/...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P <.0001); relapse/progression: 54% versus 20% (P <.0001); progression-free survival (PFS): 41% versus 58% (P <.001), and overall survival (OS): 74% versus 66% (P =.05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P <.0001) and worse PFS (RR, 2.9; P <.0001) beyond 11 months after HCT. In the first 24 months after HO', auto-HCT was associated with improved OS (RR,.41; P <.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P =.006). A landmark analysis of patients alive and progression-free at 2 years after HO' confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P <.0001) and inferior PFS (RR, 3.2; P <.0001) and OS (RR, 2.1; P =.04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- Grade 1 and 2 follicular lymphoma
- Reduced-intensity allogeneic hematopoietic cell transplantation
- Autologous hematopoietic cell transplantation
- Long-time survival
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Klyuchnikov, Evg ...
-
Bacher, Ulrike
-
Kroeger, Nicolau ...
-
Hari, Parameswar ...
-
Ahn, Kwang Woo
-
Carreras, Jeanet ...
-
visa fler...
-
Bachanova, Veron ...
-
Bashey, Asad
-
Cohen, Jonathon ...
-
D'Souza, Anita
-
Freytes, Cesar O ...
-
Gale, Robert Pet ...
-
Ganguly, Siddhar ...
-
Hertzberg, Mark ...
-
Holmberg, Leona ...
-
Kharfan-Dabaja, ...
-
Klein, Andreas
-
Ku, Grace H.
-
Laport, Ginna G.
-
Lazarus, Hillard ...
-
Miller, Alan M.
-
Mussetti, Albert ...
-
Olsson, Richard ...
-
Slavin, Shimon
-
Usmani, Saad Z.
-
Vij, Ravi
-
Wood, William A.
-
Maloney, David G ...
-
Sureda, Anna M.
-
Smith, Sonali M.
-
Hamadani, Mehdi
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Biology of blood ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet